The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

A generic product cannot enter the market until the originator product’s IP has expired, but the development process can take ...

MMS, an award-winning, data-focused clinical research organization (CRO), is showcasing its expansion as a tech-enabled, full-service Risk Evaluation and Mitigation Strategies (REMS) solutions ...

Sapio Sciences, the science-awareTM lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven ...

At least three new startups have already been launched out of the fund: U.K.-based Forth Therapeutics, French biotech ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

Ed Kaye, Stoke’s longtime leader, will be replaced by former Vertex executive Ian Smith. Elsewhere, all 12 drugmakers ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...